Fortrea

Ophthalmology Perspectives

Health EN ↓ 3 episodios

Here we explore the evolving landscape of ophthalmology clinical trials and look ahead to the most promising trends shaping the future of ophthalmology trials.

Autor

Fortrea

Categoría

Health

Web del podcast

async.com

Último episodio

20 de mar. de 2026

¿Dónde escuchar?

Podcasts en la app Replaio Radio Muy pronto

Los podcasts llegarán muy pronto a la app. Instálala ahora y sé el primero en descubrir una forma totalmente nueva de vivir los podcasts

Descárgala en Google Play Instálala gratis Android 5 M+ de descargas · valoración de 4,8 iOS muy pronto

Episodios

Ophthalmology Perspectives | Ep 3 | Gene Therapy, Patient-Centric Operations, and Risk-Benefit Challenges in Phase 1 Ophthalmology Trials 20.03.2026

Today we explore the unique challenges and opportunities in Phase 1 ophthalmology clinical trials, focusing on gene therapy and inherited retinal diseases.

Ophthalmology Perspectives | Ep 2 | Ophthalmology Trials at the Leeds CPU 20.03.2026

In today’s episode, we delve into the fascinating world of Phase 1 clinical research at Fortrea’s Leeds Clinical Pharmacology Unit in the UK. We explore the operational challenges and innovative solutions behind a recent, complex ophthalmology clinical trial.

Ophthalmology Perspectives | Ep 1 | Patient Recruitment in Ophthalmology Trials 20.03.2026

In this conversation, we to dive into the evolving landscape of patient recruitment in ophthalmology and explore how Belite Bio and Fortrea are collaborating to overcome protocol complexities, and discuss the unique opportunities Asia PAC represents for ocular development. We'll also look ahead to the most promising trends shaping the future of ophthalmology trials.

Escucha el podcast Ophthalmology Perspectives en Replaio

Radio y podcasts en una sola app - gratis y sin registro. Instálala hoy y no te pierdas el estreno

Descárgala en Google Play

Replaio no es editor de podcasts; los nombres de los programas, las portadas y el audio pertenecen a sus autores y se distribuyen a través de canales RSS públicos